Aneurysmal Subarachnoid Hemorrhage
Conditions
Keywords
aneurysmal subarachnoid hemorrhage (ASH), biomarker
Brief summary
The aim of this study is to improve the usability of biomarkers for the timely prediction of new complications following a cerebral hemorrhage, especially in combination with invasive, functional and local measurements for patients with aneurysmal subarachnoid hemorrhage (SAH). Based on analyzed biomarker profiles the chosen therapy efforts are assessed in their immediate and longer-term effectiveness.
Interventions
PROCEDUREBiomarker in serum, liquor, micro-dialysate
Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
PROCEDUREBiomarker in serum and in liquor
Single analysis of biomarker in serum and liquor
Sponsors
RWTH Aachen University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* male or female, age ≥ 18 years * signed consent for participation in the study * signed consent for further analysis of the samples collected during the clinical routine * in-patients
Exclusion criteria
* female or male patient \<18 years * pregnancy, lactation * lack of signed informed consent for participation in the study * lack of signed consent for the further analysis of the samples collected during the clinical routine * taking a study drug within the last thirty days * Simultaneous participation in another clinical trial (except participation as control group) * persons who are in a dependent relationship or employment with the sponsor or investigator * persons housed for a judicial or administrative order in an institution
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH | Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month. | Temporal development of alternative biomarkers in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH, and their response as influenced by the treatment path. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical outcome | Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month | Clinical outcome of patients depending on treatment algorithm and observed development of alternative biomarkers |
| Image morphological outcome | Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month | Image morphological outcome of patients depending on treatment algorithm and observed development of alternative biomarkers |
Countries
Germany
Contacts
Primary ContactWalid Albanna, Priv.-Doz. Dr. med.
Outcome results
None listed